| Literature DB >> 33436577 |
Cheolmin Kim1, Dong-Kyun Ryu1, Jihun Lee1, Young-Il Kim2, Ji-Min Seo1, Yeon-Gil Kim3, Jae-Hee Jeong3, Minsoo Kim1, Jong-In Kim1, Pankyeom Kim1, Jin Soo Bae1, Eun Yeong Shim1, Min Seob Lee1, Man Su Kim1, Hanmi Noh1, Geun-Soo Park1, Jae Sang Park1, Dain Son1, Yongjin An1, Jeong No Lee1, Ki-Sung Kwon1, Joo-Yeon Lee4, Hansaem Lee4, Jeong-Sun Yang4, Kyung-Chang Kim4, Sung Soon Kim4, Hye-Min Woo4, Jun-Won Kim4, Man-Seong Park5, Kwang-Min Yu2, Se-Mi Kim2, Eun-Ha Kim2, Su-Jin Park2,6, Seong Tae Jeong7, Chi Ho Yu7, Youngjo Song7, Se Hun Gu7, Hanseul Oh8, Bon-Sang Koo8, Jung Joo Hong8, Choong-Min Ryu9, Wan Beom Park10, Myoung-Don Oh10, Young Ki Choi11, Soo-Young Lee12.
Abstract
Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal antibodies (mAb) targeting the receptor binding domain (RBD) of the viral spike protein via antibody library constructed from peripheral blood mononuclear cells of a convalescent patient. The CT-P59 mAb potently neutralizes SARS-CoV-2 isolates including the D614G variant without antibody-dependent enhancement effect. Complex crystal structure of CT-P59 Fab/RBD shows that CT-P59 blocks interaction regions of RBD for angiotensin converting enzyme 2 (ACE2) receptor with an orientation that is notably different from previously reported RBD-targeting mAbs. Furthermore, therapeutic effects of CT-P59 are evaluated in three animal models (ferret, hamster, and rhesus monkey), demonstrating a substantial reduction in viral titer along with alleviation of clinical symptoms. Therefore, CT-P59 may be a promising therapeutic candidate for COVID-19.Entities:
Year: 2021 PMID： 33436577 DOI： 10.1038/s41467-020-20602-5
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919